> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Priority Review Voucher to Orchard Therapeutics
- URL: https://www.fdaweb.com/priority-review-voucher-to-orchard-therapeutics/
- Published: 2024-04-18T12:00:00.000Z
- Updated: 2026-09-14T14:28:39.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5156804

*Federal Register* notice: FDA is announcing that it issued a priority review voucher to Orchard Therapeutics for its rare pediatric disease drug approval for Lenmeldy (atidarsagene autotemcel), indicated for treating children with pre-symptomatic late infantile, pre-symptomatic early juvenile, or early symptomatic early juvenile metachromatic leukodystrophy. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2024-04-18/pdf/2024-08276.pdf?ref=fdaweb.com).